化学抗原受体T细胞在多发性骨髓瘤治疗中的作用
Zainul S Hasanali1, Beatrice Razzo1, Sandra P Susanibar-Adaniya1
1Division of Hematology/Oncology, Department of Medicine, Abramson Cancer Center, University of Pennsylvania, 3400 Civic Center Boulevard, 12th Floor South Tower, Philadelphia, PA 19104, USA.
Hematology/oncology clinics of North America
|December 29, 2023
概括
化学抗原受体T细胞 (CART) 疗法在多发性骨髓瘤中显示出高疗效,导致FDA批准. 本综述更新了已批准的产品,下一代CART和未来的挑战.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 生物技术是生物技术.
背景情况:
- 化学抗原受体T细胞 (CARTs) 利用免疫系统对抗癌症.
- 针对B细胞成熟抗原的向疗法在多发性骨髓瘤中表现出显著的疗效,导致两次FDA批准.
- 这刺激了针对这种血液性恶性瘤的基于CART的治疗方法的开发.
研究的目的:
- 为多发性骨髓瘤提供FDA批准的CART疗法的最新信息.
- 总结有关有希望的下一代多发性骨髓瘤CART候选人的数据.
- 在多发性骨髓瘤CART治疗领域概述当前的挑战和潜在的解决方案.
主要方法:
- 审查当前的文献和临床试验数据.
- 对FDA批准的CART产品进行分析.
- 评估新兴的CART技术和战略.
主要成果:
- 针对B细胞成熟抗原的两种CART疗法被FDA批准用于多发性骨髓瘤.
- 下一代CART显示出有希望的响应率和耐用性.
- 目前正在进行的研究解决了诸如抗原逃逸和毒性等挑战.
结论:
- CART疗法是多发性骨髓瘤的强大治疗方式.
- 持续创新对于克服现有挑战和改善患者治疗结果至关重要.
- 未来的方向包括优化T细胞功能和管理与治疗相关的毒性.
相关概念视频
01:27Tumor Immunotherapy
529
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
529
02:57Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K